These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 19951371)
1. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Eid AJ; Brown RA; Arthurs SK; Lahr BD; Eckel-Passow JE; Larson TS; Razonable RR Transpl Int; 2010 May; 23(5):506-13. PubMed ID: 19951371 [TBL] [Abstract][Full Text] [Related]
2. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; Garcia-Noblejas A; Clari MA; Chilet M; López J; Hernández-Boluda JC; Remigia MJ; Navarro D J Med Virol; 2010 Jul; 82(7):1208-15. PubMed ID: 20513086 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation. Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286 [TBL] [Abstract][Full Text] [Related]
5. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905 [TBL] [Abstract][Full Text] [Related]
6. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493 [TBL] [Abstract][Full Text] [Related]
7. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Cummins NW; Deziel PJ; Abraham RS; Razonable RR Transpl Infect Dis; 2009 Feb; 11(1):20-7. PubMed ID: 18811629 [TBL] [Abstract][Full Text] [Related]
8. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. Fleming T; Dunne J; Crowley B J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937 [TBL] [Abstract][Full Text] [Related]
9. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Tu W; Potena L; Stepick-Biek P; Liu L; Dionis KY; Luikart H; Fearon WF; Holmes TH; Chin C; Cooke JP; Valantine HA; Mocarski ES; Lewis DB Circulation; 2006 Oct; 114(15):1608-15. PubMed ID: 17015794 [TBL] [Abstract][Full Text] [Related]
10. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982 [TBL] [Abstract][Full Text] [Related]
11. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Ganepola S; Gentilini C; Hilbers U; Lange T; Rieger K; Hofmann J; Maier M; Liebert UG; Niederwieser D; Engelmann E; Heilbronn R; Thiel E; Uharek L Bone Marrow Transplant; 2007 Mar; 39(5):293-9. PubMed ID: 17262060 [TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection. Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559 [TBL] [Abstract][Full Text] [Related]
13. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547 [TBL] [Abstract][Full Text] [Related]
14. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181 [TBL] [Abstract][Full Text] [Related]